The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.
NCT02406846 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2015-12-30
Summary
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in pancreatic cancer could play an important role in diagnosis, predicting the risk for tumor recurrence, and providing novel target therapy biomarkers.In view of these facts, We wanted to demonstrate the value of multiparameter flow cytometry in detecting human tumor cells of pancreatic cancer in normal peripheral blood after cryosurgery with or without dendritic cell(DC)-cytokine-induced killers(CIK) treatment, and we also compared the specificity with reverse transcriptase polymerase chain reaction (RT-PCR) method.
Conditions
- Neoplastic Cells, Circulating
Interventions
- OTHER
-
Flow cytometry (FCM)
Use FCM to test PBMCs/CTCs from volunteers/patients.
- OTHER
-
RT-PCR
Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Sponsors & Collaborators
-
Fuda Cancer Hospital, Guangzhou
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2015-12-31
- Completion
- 2015-12-31
Countries
- China
Study Locations
More Related Trials
-
Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy
NCT07329920 ·Status: COMPLETED
-
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
NCT03032913 ·Status: COMPLETED
-
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
NCT05621824 ·Status: NOT_YET_RECRUITING
-
A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC
NCT06267690 ·Status: COMPLETED
-
Development of a New Immunochemistry Method Using Antibodies of Proteins Related Pancreatic Cancer
NCT04293497 ·Status: COMPLETED ·Phase: NA
-
A Phase II Study of Locally Advanced Pancreatic Cancer
NCT01867892 ·Status: UNKNOWN ·Phase: PHASE2
-
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
NCT06840067 ·Status: RECRUITING ·Phase: NA
-
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study
NCT00100321 ·Status: TERMINATED
-
Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma
NCT01474564 ·Status: COMPLETED
-
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
NCT04466189 ·Status: ENROLLING_BY_INVITATION
-
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
NCT03536793 ·Status: RECRUITING
-
Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer
NCT02934984 ·Status: UNKNOWN
-
Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities
NCT02887599 ·Status: COMPLETED ·Phase: NA
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
NCT06208436 ·Status: RECRUITING
-
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
NCT04447092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
NCT03840460 ·Status: UNKNOWN
-
Irinotecan Liposome in Combination With Capecitabine
NCT06578052 ·Status: RECRUITING ·Phase: NA
-
Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer
NCT04636788 ·Status: UNKNOWN ·Phase: NA
-
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
NCT05201729 ·Status: UNKNOWN
-
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
NCT03970252 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326 ·Status: RECRUITING ·Phase: PHASE2